探索血液性恶性瘤中核受体的关联
Mukesh Kumar Manickasamy1, Anjana Sajeev1, Bandari BharathwajChetty1
1Cancer Biology Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam, 781039, India.
Cellular and molecular life sciences : CMLS
|February 9, 2024
概括
核受体 (NR) 在血液性恶性瘤 (HM) 中起着关键作用. 针对这些受体提供了一个有希望的新策略,以改善白血病,淋巴瘤和多发性髓瘤的治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血液性恶性瘤 (HM),包括白血病,淋巴瘤和多发性骨髓瘤,具有可变的预后,经常存在复发风险.
- 目前的治疗改善了生存率,但往往导致耐药性,复发和严重的副作用,需要新的治疗点.
- 核受体 (NRs) 越来越多地被认为是它们在调节关键癌细胞与HM相关的行为中的作用.
研究的目的:
- 审查核受体 (NR) 在血液性恶性瘤 (HM) 病理生理学中的整体功能.
- 突出治疗性向NRs的潜力,以改善HM管理.
- 探索NRs作为对HM更有效的治疗干预的潜在途径.
主要方法:
- 对血液恶性瘤中核受体 (NR) 现有证据的文献综述.
- 分析NR在调节瘤细胞特征中的作用,例如增殖,分化和亡逃避.
- 检查涉及NR调制的治疗策略 (激动剂,抗剂,选择性调节剂).
主要成果:
- NRs在HM的病理生理学中发挥关键作用,影响瘤细胞的增殖,分化和生存.
- 特定的药物可以调节NR表达,这为HM治疗提供了有前途的临床影响.
- 有几种FDA批准的针对NRs的抗癌药物存在,证明了治疗潜力.
结论:
- 核受体是HM病理生理学中不可或缺的组成部分,并代表了一个可行的治疗点.
- 针对NRs提供了一个有前途的策略,以克服当前HM治疗的局限性,潜在地提高生存率和生活质量.
- 对NR向疗法的进一步研究可能会导致对血液性恶性瘤的更有效和更有效的干预.
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Role of Hematopoietic Growth Factors
1.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
The Nucleolus
8.8K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.8K
Hematopoiesis
5.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.3K


